Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Bath & Body Works, Inc. securities for the period between June 4, 2024, and November 19, 2025, due to alleged misleading statements and failure to disclose critical information regarding the company's financial performance and strategies [1][5]. Group 1: Lawsuit Details - The class action lawsuit claims that Bath & Body Works made materially false and misleading statements about its business strategies and financial guidance, which led to investor damages when the truth was revealed [5]. - The lawsuit highlights that the company's strategy of pursuing "adjacencies, collaborations and promotions" did not effectively grow its customer base or deliver the expected net sales growth [5]. - It is stated that as the company's strategy faltered, it relied on brand collaborations to mask weak financial results, ultimately leading to a failure to meet previously issued financial guidance [5]. Group 2: Participation Information - Investors who purchased Bath & Body Works securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by visiting the provided link or contacting the law firm directly for more information [3][6]. - A lead plaintiff must be appointed by March 16, 2026, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1]. Company Overview - Bath & Body Works is a specialty retailer focused on home fragrance and body care products, exploring product categories beyond its core business, including men's products, lip care, hair care, and laundry items [4]. Financial Performance and Stock Impact - On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 financial results, cutting its full-year earnings guidance by $0.03 to a range of $3.28 to $3.53 per diluted share, leading to a stock price drop of $2.18, or 6.9%, from $31.54 to $29.36 per share [6]. - Following the release of Q3 2025 financial results on November 20, 2025, which included a further reduction in full-year guidance and acknowledgment that the strategy of pursuing adjacencies had not grown the customer base, the stock fell by $5.22, or 24.8%, from $21.04 to $15.82 per share [7]. Legal Proceedings - Investors have until March 13, 2026, to request to lead the case in the ongoing lawsuit, which is filed under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 in the U.S. District Court for the Southern District of Ohio [3].

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP reminds investors of the upcoming March 16, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Bath & Body Works, Inc. ("Bath & Body Works†or the "Company†) (NYSE: BBWI) securities between June 4, 2024 and November 19, 2025, inclusive (the "Class Period†). Bath & Body Works investors have until March 16, 2026 to file a lead plaintiff motion. ...

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. for failing to disclose critical information regarding its business strategy and financial performance during the class period from June 4, 2024, to November 19, 2025 [2][6]. Allegation Details - The lawsuit alleges that Bath & Body Works did not disclose that its strategy of pursuing "adjacencies, collaborations and promotions" was ineffective in growing its customer base and did not deliver the expected growth in net sales [6]. - It is claimed that as the strategy faltered, the company relied on brand collaborations to mask weak financial results and was unlikely to meet its previously issued financial guidance [6]. - On November 20, 2025, the company reported disappointing third-quarter results, with a 1% year-over-year revenue decline, missing the guidance of 1-3% growth, and a 26% drop in net income to $77 million [6]. Financial Performance - Bath & Body Works reduced its full-year guidance for net sales and cut expected earnings per diluted share from $3.28 to "at least $2.83" [6]. - Following the announcement of its underperformance and new business strategy, the stock price fell by $5.22, or 24.8%, closing at $15.82 per share on November 20, 2025 [6]. Next Steps - Investors who purchased Bath & Body Works shares and suffered losses are encouraged to contact the law firm Bragar Eagel & Squire for more information regarding their rights and potential claims [4].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Bath & Body Works, Inc. due to alleged violations of federal securities laws, encouraging affected investors to discuss their legal options [2][4]. Financial Performance - Bath & Body Works reported a disappointing third quarter 2025, with a 1% year-over-year decline in revenue, missing prior guidance of 1-3% growth, and a 26% drop in net income to $77 million [5]. - The company significantly reduced its full-year earnings per diluted share outlook from a range of $3.28 to $3.53 to "at least $2.83" [5]. Strategic Missteps - The complaint alleges that the company's strategy of pursuing "adjacencies, collaborations and promotions" failed to grow the customer base and did not deliver the expected growth in net sales [4]. - The company admitted that its previous focus on these strategies led to reduced investment in core categories and an overreliance on promotions to mask weak financial results [5]. Stock Market Reaction - Following the disappointing financial disclosures, Bath & Body Works' stock price fell by $5.22, or 24.8%, closing at $15.82 per share on November 20, 2025 [6].

Core Viewpoint - Bath & Body Works, Inc. is facing a class action lawsuit due to alleged misleading statements regarding its growth strategy and financial performance during the specified class period from June 4, 2024, to November 19, 2025 [1] Company Overview - Bath & Body Works is a specialty retailer focused on home fragrance and body care products, and during the relevant period, it explored product categories beyond its core business, including men's products, lip care, hair care, and laundry items [3] Financial Performance - On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 results, cutting its full-year earnings guidance by $0.03 to a range of $3.28 to $3.53 per diluted share, which led to a stock price drop of $2.18, or 6.9%, from $31.54 to $29.36 [5] - Following the Q3 2025 results released on November 20, 2025, the company announced further cuts to its full-year guidance and acknowledged that its strategy of pursuing adjacencies had not grown its total customer base, resulting in a stock price decline of $5.22, or 24.8%, from $21.04 to $15.82 [6] Strategic Misalignment - Bath & Body Works claimed that customers were responding favorably to its innovation and adjacencies, asserting that its strategy was effective in driving topline growth; however, it was alleged that the strategy did not deliver the expected growth in net sales or expand the customer base [4]

Core Viewpoint - A class action has been filed against Bath & Body Works, Inc. for allegedly misleading investors regarding its business strategy and financial performance during a specified period [1][2]. Group 1: Allegations and Financial Performance - The complaint alleges that Bath & Body Works did not disclose that its strategy of pursuing "adjacencies, collaborations and promotions" was failing to grow its customer base and was not delivering the expected growth in net sales [2]. - The company reported disappointing third quarter 2025 results, with a revenue decline of 1% year over year, missing the guidance of 1-3% growth, and a net income drop of 26% to $77 million [3]. - Following the release of these results, Bath & Body Works cut its full-year guidance for net sales and reduced expected earnings per diluted share from $3.28 to "at least $2.83" [3]. Group 2: Strategic Changes - In an investor presentation, Bath & Body Works acknowledged that its previous strategy had not grown its total customer base and admitted to an over-reliance on promotions to drive growth [3]. - The company announced plans to exit certain adjacencies and refocus on its core categories to improve performance [3]. Group 3: Market Reaction - On November 20, 2025, following the disappointing financial results and strategic announcements, Bath & Body Works' stock price fell by $5.22, or 24.8%, closing at $15.82 per share [4].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. and certain senior executives for securities fraud following significant stock drops attributed to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is pending in the U.S. District Court for the Southern District of Ohio, captioned Lingam v. Bath & Body Works, Inc., et al., No. 2:26-cv-00039 [3]. - Investors have until March 13, 2026, to request to be appointed to lead the case [3]. Group 2: Company Performance and Strategy - Bath & Body Works is a specialty retailer focusing on home fragrance and body care products, exploring product categories beyond its core business, including men's products, lip care, hair care, and laundry items [4]. - The company claimed that customers were responding favorably to its innovations and that its strategy was effective in driving topline growth through category adjacencies [5]. Group 3: Stock Performance and Financial Results - On August 28, 2025, Bath & Body Works reported disappointing Q2 2025 financial results, cutting its full-year earnings guidance by $0.03 to a range of $3.28 to $3.53, leading to a stock price drop of $2.18 per share, or 6.9% [6]. - Following the Q3 2025 financial results on November 20, 2025, which revealed that the strategy of pursuing adjacencies had not grown the customer base, the stock price fell by $5.22 per share, or 24.8% [7].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit against Bath & Body Works, Inc. for allegedly misleading investors regarding its business operations during the specified class period from June 4, 2024, to November 19, 2025 [1][2]. Allegations - The lawsuit claims that Bath & Body Works made materially false and misleading statements about its growth strategy, which included "adjacencies, collaborations, and promotions," failing to grow its customer base or achieve the projected net sales growth [3]. - It is alleged that as the company's strategy faltered, it relied on brand collaborations to mask weak financial results, leading to a failure to meet previously issued financial guidance [3]. - The lawsuit asserts that the positive statements made by the defendants regarding Bath & Body Works' business and prospects were materially misleading and lacked a reasonable basis, resulting in investor damages when the truth was revealed [3]. Next Steps - Shareholders interested in participating in the class action must file their motions to serve as lead plaintiff by March 16, 2026. A lead plaintiff represents the class in directing the litigation [4]. - Shareholders can choose to remain absent from the case while still being eligible for recovery [4]. About Rosen Law Firm - Rosen Law Firm is recognized for its commitment to shareholder rights litigation, having recovered over $1 billion for shareholders since its inception [6].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. for alleged securities fraud, impacting shareholders who acquired the company's securities between June 4, 2024, and November 19, 2025 [1][2]. Financial Performance - On August 28, 2025, Bath & Body Works reported Q2 2025 earnings per diluted share of $0.30, a decline of 55.8% year over year, and net income of $64 million, down 57.9% year over year [3]. - The company cut its full-year guidance for earnings per diluted share by $0.03, adjusting it to a range of $3.28 to $3.53 [3]. - Following this announcement, the stock price fell by $2.18, or 6.9%, closing at $29.36 per share [4]. Subsequent Developments - On November 20, 2025, Bath & Body Works released Q3 2025 results, reporting a 1% decline in revenue year over year and a 26% drop in net income to $77 million [5]. - The company revised its full-year guidance for net sales from a previously positive range of 1.5%-2.7% to a negative "high single digits" and cut expected earnings per diluted share to "at least $2.83" [5]. - The stock price subsequently fell by $5.22, or 24.8%, closing at $15.82 per share [6]. Allegations in the Lawsuit - The lawsuit alleges that the company made materially false and misleading statements and failed to disclose adverse facts about its business and operations [7]. - Specific allegations include the failure to disclose that the strategy of pursuing "adjacencies, collaborations, and promotions" was not effective in growing the customer base or delivering expected sales growth [7][8]. - It is claimed that the company relied on brand collaborations to mask weak financial results and was unlikely to meet its previously issued financial guidance [8].